Affimed Therapeutics
Priced, Nasdaq: AFMDBiotech developing immunotherapies for lymphomas, leukemia and other cancers.
Industry: Health Care
First Day Return: -18.6%
AFMD
Biotech developing immunotherapies for lymphomas, leukemia and other cancers.
| IPO Date | 09/11/2014 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | Heidelberg, Germany |
|---|---|
| Founded | 2000 |
| Employees at IPO | 53 |
| Website www.affimed.com | |
IPO News for Affimed Therapeutics
Affimed Therapeutics (AFMD) Performance
